In a report released yesterday, Stephanie Davis from Barclays reiterated a Buy rating on Health Catalyst (HCAT – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $8.47.
Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Laboratory, and McKesson. According to TipRanks, Davis has an average return of -7.0% and a 41.75% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Health Catalyst with a $13.25 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.87 and a one-year low of $6.60. Currently, Health Catalyst has an average volume of 544.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst Reports Fourth Quarter and Year End 2023 Results
- Health Catalyst’s Abe Health Registry receives QPP approval
- Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
